Clinical Connection

This trial is not actively recruiting.

This trial has completed recruitment on this platform, and is no longer accepting new referrals.

SGN35-028: A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL) or peripheral T cell lymphoma (PTCL)

A retreatment study with brentuximab vedotin in subjects with classical Hodgkin lymphoma or peripheral T cell lymphoma whose cancer got better after taking brentuximab vedotin, and subsequently got worse. USM/BVM/2021/0037

Trial ID: NCT03947255

Trial Details

Please visit https://clinicaltrials.gov/study/NCT03947255 for more information.

Estimated Enrollment

80 Participants

Phase

2

Eligibility Criteria

Participants must:

This study is no longer recruiting participants. Please visit https://clinicaltrials.gov/study/NCT03947255 for more information.

Participants must not:

This study is no longer recruiting participants. Please visit https://clinicaltrials.gov/study/NCT03947255 for more information.

What Will Happen in This Study

Please visit https://clinicaltrials.gov/study/NCT03947255 for more information.

Frequently Asked Questions (FAQs)